Abstract:Plasma hemopexin (HPX) is the key antioxidant protein of the endogenous clearance pathway that limits the deleterious effects of heme released from hemoglobin and myoglobin (the term “heme” is used in this article to denote both the ferrous and ferric forms). During intra-vascular hemolysis, heme partitioning to protein and lipid increases as the plasma concentration of HPX declines. Therefore, the development of HPX as a replacement therapy during high heme stress could be a relevant intervention for hemolytic disorders. A logical approach to enhance HPX yield involves recombinant production strategies from human cell lines. The present study focuses on a biophysical assessment of heme binding to recombinant human HPX (rhHPX) produced in the Expi293FTM (HEK293) cell system. In this report, we examine rhHPX in comparison with plasma HPX using a systematic analysis of protein structural and functional characteristics related to heme binding. Analysis of rhHPX by UV/Vis absorption spectroscopy, circular dichroism (CD), size-exclusion chromatography (SEC)-HPLC, and catalase-like activity demonstrated a similarity to HPX fractionated from plasma. In particular, the titration of HPX apo-protein(s) with heme was performed for the first time using a wide range of heme concentrations to model HPX–heme interactions to approximate physiological conditions (from extremely low to more than two-fold heme molar excess over the protein). The CD titration data showed an induced bisignate CD Soret band pattern typical for plasma and rhHPX versions at low heme-to-protein molar ratios and demonstrated that further titration is dependent on the amount of protein-bound heme to the extent that the arising opposite CD couplet results in a complete inversion of the observed CD pattern. The data generated in this study suggest more than one binding site in both plasma and rhHPX. Furthermore, our study provides a useful analytical platform for the detailed characterization of HPX–heme interactions and potentially novel HPX fusion constructs.

Histidine-rich glycoprotein: the Swiss Army knife of mammalian plasma

Histidine-rich glycoprotein: A novel adaptor protein in plasma that modulates the immune, vascular and coagulation systems

Histidine-rich Glycoprotein (HRGP): Pleiotropic and Paradoxical Effects on Macrophage, Tumor Microenvironment, Angiogenesis, and Other Physiological and Pathological Processes

Histidine-rich Glycoprotein Modulates the Blood-vascular System in Septic Condition

The histidine-rich glycoprotein of serum has a domain rich in histidine, proline, and glycine that binds heme and metals

Histidine-rich glycoprotein functions cooperatively with cell surface heparan sulfate on phagocytes to promote necrotic cell uptake

Genotype-dependent N-glycosylation and newly exposed O-glycosylation affect plasmin-induced cleavage of histidine-rich glycoprotein (HRG)

Activated Platelets Provide a Functional Microenvironment for the Antiangiogenic Fragment of Histidine-Rich Glycoprotein.

Human histidine-rich glycoprotein: simultaneous purification with antithrombin III and characterization of its gross structure

A heme- and metal-binding hexapeptide from the sequence of rabbit plasma histidine-rich glycoprotein

Histidine-Rich Glycoprotein Prevents Septic Lethality Through Regulation of Immunothrombosis and Inflammation

Preferred heme binding sites of histidine-rich glycoprotein

Prognostic Value of Histidine-Rich Glycoprotein for Community-Acquired Pneumonia

Histidine-rich glycoprotein modulates neutrophils and thrombolysis-associated hemorrhagic transformation

[Role of histidine-rich glycoprotein as anti-DAMPs and therapeutic effects on DAMPs-related diseases]

Effects of Histidine-rich glycoprotein on erythrocyte aggregation and hemolysis: Implications for a role under septic conditions

Protein disulfide isomerase cleaves allosteric disulfides in histidine-rich glycoprotein to regulate thrombosis

Human Plasma and Recombinant Hemopexins: Heme Binding Revisited

C-reactive protein: structure, function, regulation, and role in clinical diseases

Incorporation of a circulating protein into megakaryocyte and platelet granules.

Binding Site on Human Immunoglobulin G for the Affinity Ligand HWRGWV.